Astra Zeneca seeks emergency approval from the FDA for its new antibody therapy;
together with the developments from Merck, COVID becomes more and more manageable for breakthrough and immo-compromised individuals.
The antibody therapy, called AZD7442, was 77% effective in reducing the risk of developing Covid-19 symptoms among people who received the drug as a preventive measure, AstraZeneca said in a press release, citing its Phase III trail featuring over 5,000 participants.
According to the drugmaker, the antibody cocktail could be used to protect people who may not develop a robust immune response to Covid-19 vaccines.
ADO Charting and Technical Analysis, page-2160
-
- There are more pages in this discussion • 7,215 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.002(8.70%) |
Mkt cap ! $52.28M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $20.83K | 964.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2247357 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 164375 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |